INVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In Allergan plc To...
November 18 2016 - 11:45PM
Business Wire
The securities litigation law firm of Brower Piven, A
Professional Corporation, announces that a class action lawsuit has
been commenced in the United States District Court for the Southern
District of New York on behalf of purchasers of Allergan plc (NYSE:
AGN) (“Allergan” or the “Company”) securities during the period
between February 25, 2014 and November 2, 2016, inclusive (the
“Class Period”). Investors who wish to become proactively involved
in the litigation have until January 3, 2017 to seek appointment as
lead plaintiff.
If you wish to choose counsel to represent you and the Class,
you must apply to be appointed lead plaintiff and be selected by
the Court. The lead plaintiff will direct the litigation and
participate in important decisions including whether to accept a
settlement for the Class in the action. The lead plaintiff will be
selected from among applicants claiming the largest loss from
investment in Allergan securities during the Class Period. Members
of the Class will be represented by the lead plaintiff and counsel
chosen by the lead plaintiff. No class has yet been certified in
the above action.
The complaint accuses the defendants of violations of the
Securities Exchange Act of 1934 by virtue of the defendants’
failure to disclose during the Class Period that Allergan plc and
Actavis plc were engaging and/or had engaged in conduct that would
result in an antitrust investigation by the U.S. Department of
Justice (“DOJ”), the DOJ investigation and the underlying conduct
could cause prosecutors to file criminal charges for suspected
price collusion, and between 2014-2015, the companies lacked
effective internal controls over financial reporting.
According to the complaint, following an August 6, 2016 filing
and article announcing that the Company had received a subpoena
from the DOJ relating to marketing and pricing, and a November 3,
2016 article revealing that prosecutors may file criminal charges,
the value of Allergan shares declined significantly.
If you have suffered a loss in excess of $100,000 from
investment in Allergan securities purchased on or after February
25, 2014 and held through the revelation of negative information
during and/or at the end of the Class Period and would like to
learn more about this lawsuit and your ability to participate as a
lead plaintiff, without cost or obligation to you, please visit our
website at http://www.browerpiven.com/currentsecuritiescases.html.
You may also request more information by contacting Brower Piven
either by email at hoffman@browerpiven.com or by telephone at (410)
415-6616. Brower Piven also encourages anyone with information
regarding the Company’s conduct during the period in question to
contact the firm, including whistleblowers, former employees,
shareholders and others.
Attorneys at Brower Piven have extensive experience in
litigating securities and other class action cases and have been
advocating for the rights of shareholders since the 1980s. If you
choose to retain counsel, you may retain Brower Piven without
financial obligation or cost to you, or you may retain other
counsel of your choice. You need take no action at this time to be
a member of the class.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20161118005590/en/
Brower Piven, A Professional CorporationCharles J. Piven,
410-415-66161925 Old Valley RoadStevenson, Maryland
21153hoffman@browerpiven.com
Allergan (NYSE:AGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Allergan (NYSE:AGN)
Historical Stock Chart
From Apr 2023 to Apr 2024